ʻO Azithromycin
| Inoa mea kūʻai | AZITHROMYCIN | ||
| CAS | 83905-01-5 | ||
| KANAWAI HS | 29419090 | ||
| Pau hala | 5 mau makahiki | ||
| Maʻamau | EP i kēia manawa | ||
| Helehelena | Keʻokeʻo a ʻaneʻane keʻokeʻo crystalline pauka | ||
| Solubility | Hoʻomaʻemaʻe ʻole ʻia i ka wai, hiki ʻole ke hoʻoheheʻe ʻia i ka etanol anhydrous a me ka inmethylene chloride | ||
| ʻIlika ʻike | Kūlike me Azithromycin RSS e maopopo a kala ʻole. Ma waena o 9.0 a me l1.0 Ma waena o -45 a me -49 | ||
| Nā mea pili | Haumia L | ≤0.5% | |
| Haumia M | ≤0.5% | ||
| Haumia E. | ≤0.5% | ||
| Haumia F | ≤0.5% | ||
| Haumia D a me J | ≤0.5% | ||
| Haumia I | ≤0.5% | ||
| Haumia C | ≤0.5% | ||
| Haumia N | ≤0.5% | ||
| Haumia H | ≤0.5% | ||
| Haumia A | ≤0.5% | ||
| Haumia P | ≤0.5% | ||
| Ka maʻemaʻe ʻole O | ≤0.5% | ||
| Haumia G. | ≤0.2% | ||
| Haumia B | ≤2.0% | ||
| Kekahi haumia ʻē aʻe | ≤0.2% | ||
| Huina haumia | ≤3.0% | ||
| Kaha kaumaha s | ≤25ppm | ||
| Wai | 1.8% -6.8% | ||
| ʻAhu lehu | ≤0.2% | ||
| Assay Ma ke kumu anhydrous | 98.3% | ||
| Nā mea hoʻoheheʻe koena | Acetone | ≤3200ppm | |
| Metanol | ≤3000ppm | ||
| Dichloromethane | ≤600ppm | ||
| ʻIke nui | 0.35 ~ 0.65g / ml | ||
| Paʻa kī | 0.65 ~ 0.85g / ml | ||
| Hoʻohālikelike ka nui o ka huna huna | ≥80% 40mesh | ||
| hana | Loaʻa ka puʻuwai ikaika a me nā hopena neuroprotective ʻo Carvedilol: ʻokoʻa ka antagonists β-receptor maʻamau, hoʻohana lōʻihi o kēia huahana i nā mea maʻi hypertensive ʻaʻole hiki ke hoʻonui i nā moku coronary a me nā puʻuwai, hōʻemi i ke kūpaʻa vipher peripheral, akā hoʻoliʻiliʻi hoʻi i ka ʻōnaehana ʻōnaehana. A me ke kūpaʻa o ka pulmonary, e kāohi pono i ke kaomi kiʻekiʻe. He hopena pale kā kēia huahana ma ka hana renal, ʻaʻole ia e loli i ke kahe o ke kōkō, akā hoʻemi ʻia ka microalbuminuria, hoʻoliʻiliʻi i ke kūpaʻa venal a me ka hopena maikaʻi o ke kaohi i nā lipids koko. | ||
Kākau i kāu leka ma aneʻi a hoʻouna iā mākou
